Multicenter Analysis of Standard of Care Versus Oxandrolone Versus Testosterone in Burn HypermetaboliSm (MASCOTS)
Journal of Burn Care & Research · 04.11.2026 · 47 (6) · 1778-1790
DOI: 10.1093/jbcr/irag127 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Burn Care & Research, online erschienen am 28.07.2026. Verfasst von Aaron Hong und 34 weiteren Autor:innen. Beteiligte Einrichtung: Louisiana State University-New Orleans Health Sciences Center, Department of Surgery, New Orleans, LA 70112, United States. Hauptthemen laut MEDLINE: Oxandrolone, Burns, Testosterone, Anabolic Agents. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
Severe burn injury results in a profound hypermetabolic state that complicates management and recovery. Oxandrolone has historically been used to help attenuate this response, but its withdrawal from the United States (US) market has led to increased use of alternative anabolic agents such as testosterone and human growth hormone (HGH). However, studies comparing the efficacy and safety between these alternative anabolic agents in adult burn patients remain limited. In this multicenter study, patients were stratified based on if they received testosterone, oxandrolone, HGH, or no anabolic supplementation. Baseline characteristics and clinical outcomes were analyzed with analysis of variance and Chi-square testing as appropriate. Propensity score matching was used to adjust for baseline differences in injury severity and patient characteristics. 813 patients who sustained major burn injuries between June 2022 and June 2025 across 12 verified US burn centers were analyzed. Anabolic supplementation was not associated with improved inpatient weight maintenance when compared with no anabolic supplementation (P = .064), nor with differences in median weight change. Patients receiving anabolic therapy experienced longer hospital and intensive care unit stays (P = .026). Overall mortality did not differ between treated and untreated patients (P = .885); however, mortality was higher among patients treated with oxandrolone compared with testosterone (P = .001). Anabolic therapy was associated with higher rates of venous thromboembolic events (P = .019). These findings underscore that optimizing anabolic therapy will require balancing efficacy, safety, and economic considerations, with a focus on long-term functional outcomes beyond initial hospital stay.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Louisiana State University-New Orleans Health Sciences Center, Department of Surgery, New Orleans, LA 70112, United States.
- Louisiana State University-New Orleans Health Sciences Center, School of Medicine, New Orleans, LA 70112, United States.
- Louisiana State University-New Orleans Health Sciences Center, Community Health Science and Policy, New Orleans, LA 70112, United States.
- University Medical Center New Orleans, Burn Center, New Orleans, LA 70112, United States.
- Tulane University School of Medicine, Department of Surgery, New Orleans, LA 70112, United States.
- Louisiana State University Health and Sciences Center and University Medical Center, Department of Surgery, Burn Center at University Medical Center New Orleans, New Orleans, LA 70112, United States.
ORCID-Profile: Aaron Hong, Parker M Hannan, Anastasiya Ivanko, Denise M Danos, Gina L DeFelice, Jonathan E Schoen, Jeffrey Carter, Rebecca Coffey, Lauren B Nosanov, Bo Hyun Kong, Megan Taylor Yoerg, Laura S Johnson, Robel T Beyene, Sarah V Cogle, Anne Wagner, Arpana Jain, Hope Werenski, David M Hill, Christopher LaChapelle, Callie M Thompson, Rohit Mittal, Steven Kahn, Shawn Tejiram, Melissa McLawhorn, Emma Blomberg, Justin Suarez, Shady Al-Hayek, Allison N Boyd, M Victoria P Miles
Zitieren
APA
Hong, A., Hannan, P. M., Ivanko, A., Danos, D. M., DeWitt Davis, A., DeFelice, G. L., Schoen, J. E., Carter, J., Faris, J., Coffey, R., Nosanov, L. B., Kong, B. H., Yoerg, M. T., Johnson, L. S., Beyene, R. T., Cogle, S. V., Wagner, A., Jain, A., Foster, K., …, & Miles, M. V. P. (2026). Multicenter Analysis of Standard of Care Versus Oxandrolone Versus Testosterone in Burn HypermetaboliSm (MASCOTS). Journal of Burn Care & Research, 47(6), 1778-1790. https://doi.org/10.1093/jbcr/irag127
Vancouver
Hong A, Hannan PM, Ivanko A, Danos DM, DeWitt Davis A, DeFelice GL, et al. Multicenter Analysis of Standard of Care Versus Oxandrolone Versus Testosterone in Burn HypermetaboliSm (MASCOTS). Journal of Burn Care & Research. 2026;47(6):1778-1790. doi:10.1093/jbcr/irag127
BibTeX
@article{Hong2026,
author = {Hong, Aaron and Hannan, Parker M and Ivanko, Anastasiya and Danos, Denise M and DeWitt Davis, Alexandra and DeFelice, Gina L and Schoen, Jonathan E and Carter, Jeffrey and Faris, Janie and Coffey, Rebecca and Nosanov, Lauren B and Kong, Bo Hyun and Yoerg, Megan Taylor and Johnson, Laura S and Beyene, Robel T and Cogle, Sarah V and Wagner, Anne and Jain, Arpana and Foster, Kevin and Werenski, Hope and Holmes, James H and Hill, David M and Hassouba, Mahmoud and LaChapelle, Christopher and Thompson, Callie M and Johnson, Adria and Mittal, Rohit and Kahn, Steven and Tejiram, Shawn and McLawhorn, Melissa and Blomberg, Emma and Suarez, Justin and Al-Hayek, Shady and Boyd, Allison N and Miles, M Victoria P},
title = {Multicenter Analysis of Standard of Care Versus Oxandrolone Versus Testosterone in Burn HypermetaboliSm (MASCOTS)},
journal = {Journal of Burn Care & Research},
year = {2026},
volume = {47},
number = {6},
pages = {1778--1790},
doi = {10.1093/jbcr/irag127}
}
EUVIMED